Expert campus | Focus on tuberculosis
Supported by:
Moderation & Introduction:
- Santiago Ramón-García, Research & Development Agency of Aragon (ARAID) Foundation & Mycobacterial Genetics Group, Dept. of Microbiology, University of Zaragoza
- Ruben Hartkoorn – Institut Pasteur de Lille, INSERM
This content has been restricted to logged in users only. Please login to view this content.
Speakers:
- Michel Pieren – Project Manager, BioVersys AG, CH
This content has been restricted to logged in users only. Please login to view this content.
- Florian Kloss – Head, Hans Knöll Institute (HKI), GER
- Michael Hoelscher – Network Coordinator, Ludwig-Maximilians-University Munich (LMU), GER
This content has been restricted to logged in users only. Please login to view this content.
Play Video
This might also be of interest for you:
- Development of novel treatments to treat TB is in the focus of the IMI AMR Accelerator > Please find here more information about the ongoing projects: ERA4TB, TRIC-TB
- Updated WHO information on TB & Covid-19, 12 May
Article by ERA4TB & Stop TB Partnership, 20 May: The potential impact of the Covid-19 response on tuberculosis in high-burden countries: a modelling analysis - Harvard Medical School, 5 August: New generation of drugs show early efficacy against drug-resistant TB
- Press release by LMU Munich & Leibniz HKI, 19 Nov 2019: New drug substance BTZ-043 is being tested on patients for the first time
- BioVersys AG in the AMR Stakeholder Guide